An open label,3 month study evaluating effect of Istradefylline on daytime sleepiness and sleep disturbances in patients with Parkinson's disease

Trial Profile

An open label,3 month study evaluating effect of Istradefylline on daytime sleepiness and sleep disturbances in patients with Parkinson's disease

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Jul 2017

At a glance

  • Drugs Istradefylline (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Jul 2017 New trial record
    • 08 Jun 2017 Results presented at the 21st International Congress of Parkinson's Disease and Movement Disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top